MA52483A - Dérivés de gip et leurs utilisations - Google Patents
Dérivés de gip et leurs utilisationsInfo
- Publication number
- MA52483A MA52483A MA052483A MA52483A MA52483A MA 52483 A MA52483 A MA 52483A MA 052483 A MA052483 A MA 052483A MA 52483 A MA52483 A MA 52483A MA 52483 A MA52483 A MA 52483A
- Authority
- MA
- Morocco
- Prior art keywords
- gip derivatives
- gip
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2235—Secretins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/645—Secretins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862666916P | 2018-05-04 | 2018-05-04 | |
| EP18172827 | 2018-05-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52483A true MA52483A (fr) | 2021-03-10 |
Family
ID=66440040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052483A MA52483A (fr) | 2018-05-04 | 2019-05-03 | Dérivés de gip et leurs utilisations |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10604555B2 (fr) |
| EP (1) | EP3788063B1 (fr) |
| JP (2) | JP6818940B2 (fr) |
| KR (1) | KR102379958B1 (fr) |
| CN (1) | CN112074531B (fr) |
| AU (1) | AU2019263674B2 (fr) |
| BR (1) | BR112020022027A2 (fr) |
| CA (1) | CA3097939A1 (fr) |
| CL (1) | CL2020002796A1 (fr) |
| CO (1) | CO2020014180A2 (fr) |
| ES (1) | ES2961384T3 (fr) |
| IL (1) | IL278171A (fr) |
| MA (1) | MA52483A (fr) |
| MX (1) | MX2020011427A (fr) |
| PE (1) | PE20210473A1 (fr) |
| PH (1) | PH12020551742A1 (fr) |
| RU (1) | RU2020136305A (fr) |
| SG (1) | SG11202010297UA (fr) |
| TW (1) | TWI707865B (fr) |
| WO (1) | WO2019211451A1 (fr) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR109596A1 (es) | 2016-09-09 | 2018-12-26 | Incyte Corp | Compuestos pirazolopiridina y sus usos |
| US20180072741A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyrimidine compounds and uses thereof |
| US20180072718A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| DK3755703T3 (da) | 2018-02-20 | 2022-06-27 | Incyte Corp | N-(phenyl)-2-(phenyl)pyrimidin-4-carboxamidderivater og relaterede forbindelser som hpk1-inhibitorer til behandling af kræft |
| US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
| PE20210473A1 (es) * | 2018-05-04 | 2021-03-08 | Novo Nordisk As | Derivados de gip y usos de estos |
| US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| KR20220059480A (ko) | 2019-08-06 | 2022-05-10 | 인사이트 코포레이션 | 고체 형태의 hpk1 억제제 |
| IL295109A (en) * | 2020-02-05 | 2022-09-01 | Lilly Co Eli | Resin miners in a serial peptide synthesizer |
| WO2021175974A1 (fr) | 2020-03-06 | 2021-09-10 | Sanofi | Peptides servant d'agonistes sélectifs du récepteur gip |
| EP4171662A1 (fr) * | 2020-03-31 | 2023-05-03 | Antaros Medical AB | Agonistes sélectifs du récepteur de gip comprenant une fraction chélatante à des fins d'imagerie et de thérapie |
| US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
| AU2021312323A1 (en) | 2020-07-22 | 2023-02-02 | Novo Nordisk A/S | Co-agonists at GLP-1 and GIP receptors suitable for oral delivery |
| JP2023534130A (ja) * | 2020-07-22 | 2023-08-08 | ノヴォ ノルディスク アー／エス | Ｇｌｐ－１受容体およびｇｉｐ受容体共作動薬 |
| IL302745A (en) * | 2020-11-09 | 2023-07-01 | Embark Biotech Aps | Compounds and their use in the treatment of tachykinin receptor mediated disorders |
| BR112023025201A2 (pt) | 2021-06-23 | 2024-02-27 | Peptron Inc | Composição de formulação de liberação sustentada compreendendo semaglutida, método para a produção de uma composição de formulação de liberação sustentada e uso da dita composição para tratar diabetes, obesidade, esteato-hepatite não alcoólica ou doença cerebral degenerativa |
| WO2023031455A1 (fr) | 2021-09-06 | 2023-03-09 | Sanofi Sa | Nouveaux peptides utilisés en tant qu'agonistes puissants et sélectifs du récepteur de gip |
| WO2023118263A1 (fr) * | 2021-12-21 | 2023-06-29 | Embark Biotech Aps | Agonistes pour le traitement d'un trouble de l'alimentation |
| TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
| WO2023151594A1 (fr) * | 2022-02-11 | 2023-08-17 | Hangzhou Sciwind Biosciences Co., Ltd. | Composition comprenant des agonistes du récepteur gip et des agonistes du récepteur glp-1 et son utilisation |
| KR20240095076A (ko) | 2022-12-16 | 2024-06-25 | 주식회사 펩트론 | Glp-1 수용체 작용제 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 미립구 및 이의 용도 |
| CN118255864A (zh) * | 2022-12-26 | 2024-06-28 | 杭州中美华东制药有限公司 | Gip受体激动剂及其用途 |
| GB202302686D0 (en) * | 2023-02-24 | 2023-04-12 | Imperial College Innovations Ltd | Novel compounds |
| AU2024224775A1 (en) * | 2023-02-24 | 2025-10-09 | Ip2Ipo Innovations Limited | Compounds |
| CN120659805A (zh) * | 2023-10-31 | 2025-09-16 | 深圳信立泰药业股份有限公司 | Glp-1化合物及其制备方法与应用 |
| CN120349392A (zh) * | 2023-11-06 | 2025-07-22 | 成都奥达生物科技有限公司 | 一种gip激动剂化合物 |
| WO2025176999A2 (fr) * | 2024-02-23 | 2025-08-28 | Ip2Ipo Innovations Limited | Nouveaux composés |
| WO2026119941A1 (fr) * | 2024-12-05 | 2026-06-11 | F. Hoffmann-La Roche Ag | Synthèse spps d'un peptide comprenant une chaîne latérale d'acide gras |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE272650T1 (de) * | 1999-03-29 | 2004-08-15 | Uutech Ltd | Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes |
| GB0404124D0 (en) | 2004-02-25 | 2004-03-31 | Univ Ulster | Antagonists of GIP |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| ES2558842T3 (es) | 2008-06-17 | 2016-02-09 | Indiana University Research And Technology Corporation | Agonistas mixtos a base de GIP para el tratamiento de trastornos metabólicos y obesidad |
| KR20130133103A (ko) * | 2008-08-07 | 2013-12-05 | 입센 파마 에스.에이.에스 | Ｎ-말단이 변형된 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드(ｇｉｐ)의 유사체 |
| ES2574835T3 (es) | 2008-08-07 | 2016-06-22 | Ipsen Pharma S.A.S. | Análogos del polipéptido insulinotrópico dependiente de glucosa |
| CA2733005C (fr) | 2008-08-07 | 2016-09-27 | Ipsen Pharma S.A.S. | Analogues tronques de polypeptide insulinotrope glucose-dependant |
| CA2732949C (fr) | 2008-08-07 | 2016-12-20 | Ipsen Pharma S.A.S. | Analogues de polypeptide insulinotrope glucose-dependant |
| US20120329711A1 (en) | 2009-12-16 | 2012-12-27 | Nordisk A/S | Glp-1 receptor agonist compounds with a modified n-terminus |
| KR20120123443A (ko) | 2010-01-27 | 2012-11-08 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트 |
| ES2661228T3 (es) | 2010-05-13 | 2018-03-28 | Indiana University Research And Technology Corporation | Péptidos de la superfamilia de glucagón que muestran actividad de receptor nuclear de hormona |
| RU2012153753A (ru) | 2010-05-13 | 2014-06-20 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Пептиды глюкагонового суперсемейства, обладающие активностью в отношении сопряженных с g-белком рецепторов |
| US9249181B2 (en) | 2010-09-13 | 2016-02-02 | Amylin Pharmaceuticals, Llc | C-terminal amidation of polypeptides |
| US9023986B2 (en) * | 2010-10-25 | 2015-05-05 | Hoffmann-La Roche Inc. | Glucose-dependent insulinotropic peptide analogs |
| RU2013133803A (ru) | 2010-12-22 | 2015-01-27 | Маркадиа Байотек, Инк. | Способы лечения метаболических нарушений и ожирения при помощи пептидов на основе глюкагона, активных по отношению к рецепторам гип и гпп |
| KR102002783B1 (ko) * | 2011-06-10 | 2019-07-24 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | 포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용 |
| WO2013003449A2 (fr) | 2011-06-27 | 2013-01-03 | Phasebio Pharmaceuticals, Inc. | Méthodes de traitement par des agonistes de récepteur du glp-1 |
| CA2872314C (fr) * | 2012-05-03 | 2021-08-31 | Zealand Pharma A/S | Composes agonistes doubles du gip-glp-1 et methodes |
| SI2864350T1 (en) | 2012-06-21 | 2018-08-31 | Indiana University Research And Technology Corporation | GLUCAGON ANALOGUE ANALOGUE WITH ACTIVITY OF GIP RECEPTOR |
| ES2602486T3 (es) * | 2012-06-21 | 2017-02-21 | Indiana University Research And Technology Corporation | Análogos de glucagón que muestran actividad de receptor de GIP |
| JP6538645B2 (ja) | 2013-03-14 | 2019-07-03 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | インスリン‐インクレチン複合物 |
| BR112015025464A2 (pt) | 2013-04-18 | 2017-10-10 | Novo Nordisk As | coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico |
| DK3004155T3 (da) | 2013-05-28 | 2022-01-03 | Takeda Pharmaceuticals Co | Peptidforbindelse |
| CN105451776B (zh) | 2013-08-15 | 2020-04-17 | 诺和诺德股份有限公司 | Glp-1衍生物及其用途 |
| WO2015022420A1 (fr) | 2013-08-16 | 2015-02-19 | Medimmune Limited | Agonistes doubles de récepteur de gip et glp-1 pour le traitement du diabète |
| CA2929459C (fr) | 2013-11-06 | 2022-05-03 | Zealand Pharma A/S | Composes agonistes doubles de gip et glp-1 et procedes associes |
| AU2014345570B2 (en) | 2013-11-06 | 2019-01-24 | Zealand Pharma A/S | Glucagon-GLP-1-GIP triple agonist compounds |
| JP2017525656A (ja) * | 2014-06-04 | 2017-09-07 | ノヴォ ノルディスク アー／エス | 医療用のｇｌｐ−１／グルカゴン受容体コアゴニスト |
| WO2016034186A1 (fr) | 2014-09-05 | 2016-03-10 | University Of Copenhagen | Analogues peptidiques de gip |
| EP3212218B1 (fr) | 2014-10-29 | 2021-06-30 | Zealand Pharma A/S | Composés agonistes de gip et procédés associés |
| JP6730278B2 (ja) * | 2014-11-27 | 2020-07-29 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１誘導体及びその使用 |
| AR103242A1 (es) * | 2015-01-09 | 2017-04-26 | Lilly Co Eli | Compuestos co-agonistas de gip y glp-1 |
| JP2018506571A (ja) | 2015-02-27 | 2018-03-08 | リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ | Ｒｈｏ関連プロテインキナーゼの阻害及び疾患の治療のためのインダゾリルチアジアゾールアミン及び関連する化合物 |
| EP3310376A4 (fr) | 2015-06-17 | 2019-01-23 | The California Institute for Biomedical Research | Agents thérapeutiques modifiés et compositions associées |
| EP3430033A4 (fr) | 2016-03-18 | 2019-11-20 | Merck Sharp & Dohme Corp. | Conjugués d'insuline-incrétine |
| WO2017210168A1 (fr) | 2016-06-02 | 2017-12-07 | Indiana University Research And Technology Corporation | Agonistes hydrosolubles et chimiquement stables du depsi-glucagon |
| US11572399B2 (en) | 2017-05-31 | 2023-02-07 | University Of Copenhagen | Long-acting GIP peptide analogues |
| PE20210473A1 (es) * | 2018-05-04 | 2021-03-08 | Novo Nordisk As | Derivados de gip y usos de estos |
-
2019
- 2019-05-03 PE PE2020001751A patent/PE20210473A1/es unknown
- 2019-05-03 BR BR112020022027-2A patent/BR112020022027A2/pt not_active Application Discontinuation
- 2019-05-03 US US16/403,241 patent/US10604555B2/en active Active
- 2019-05-03 JP JP2020512588A patent/JP6818940B2/ja active Active
- 2019-05-03 TW TW108115352A patent/TWI707865B/zh not_active IP Right Cessation
- 2019-05-03 US US17/052,702 patent/US11633459B2/en active Active
- 2019-05-03 SG SG11202010297UA patent/SG11202010297UA/en unknown
- 2019-05-03 MX MX2020011427A patent/MX2020011427A/es unknown
- 2019-05-03 MA MA052483A patent/MA52483A/fr unknown
- 2019-05-03 WO PCT/EP2019/061413 patent/WO2019211451A1/fr not_active Ceased
- 2019-05-03 RU RU2020136305A patent/RU2020136305A/ru unknown
- 2019-05-03 EP EP19722582.4A patent/EP3788063B1/fr active Active
- 2019-05-03 CA CA3097939A patent/CA3097939A1/fr not_active Withdrawn
- 2019-05-03 KR KR1020207034171A patent/KR102379958B1/ko not_active Expired - Fee Related
- 2019-05-03 CN CN201980029824.2A patent/CN112074531B/zh active Active
- 2019-05-03 ES ES19722582T patent/ES2961384T3/es active Active
- 2019-05-03 AU AU2019263674A patent/AU2019263674B2/en not_active Ceased
-
2020
- 2020-04-09 JP JP2020070421A patent/JP2020125311A/ja not_active Withdrawn
- 2020-10-20 PH PH12020551742A patent/PH12020551742A1/en unknown
- 2020-10-20 IL IL278171A patent/IL278171A/en unknown
- 2020-10-28 CL CL2020002796A patent/CL2020002796A1/es unknown
- 2020-11-12 CO CONC2020/0014180A patent/CO2020014180A2/es unknown
-
2023
- 2023-02-03 US US18/105,419 patent/US20240190938A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020022027A2 (pt) | 2021-02-02 |
| CA3097939A1 (fr) | 2019-11-07 |
| TW202003550A (zh) | 2020-01-16 |
| EP3788063B1 (fr) | 2023-08-09 |
| EP3788063C0 (fr) | 2023-08-09 |
| CN112074531B (zh) | 2025-04-15 |
| EP3788063A1 (fr) | 2021-03-10 |
| CL2020002796A1 (es) | 2021-02-19 |
| US11633459B2 (en) | 2023-04-25 |
| US10604555B2 (en) | 2020-03-31 |
| RU2020136305A (ru) | 2022-05-05 |
| AU2019263674B2 (en) | 2023-03-02 |
| MX2020011427A (es) | 2020-12-07 |
| US20190367578A1 (en) | 2019-12-05 |
| PH12020551742A1 (en) | 2021-06-28 |
| US20240190938A1 (en) | 2024-06-13 |
| SG11202010297UA (en) | 2020-11-27 |
| JP2020125311A (ja) | 2020-08-20 |
| KR102379958B1 (ko) | 2022-04-01 |
| WO2019211451A1 (fr) | 2019-11-07 |
| CO2020014180A2 (es) | 2021-01-29 |
| US20220000982A1 (en) | 2022-01-06 |
| ES2961384T3 (es) | 2024-03-11 |
| KR20210005700A (ko) | 2021-01-14 |
| CN112074531A (zh) | 2020-12-11 |
| AU2019263674A1 (en) | 2020-11-26 |
| IL278171A (en) | 2020-11-30 |
| PE20210473A1 (es) | 2021-03-08 |
| JP6818940B2 (ja) | 2021-01-27 |
| TWI707865B (zh) | 2020-10-21 |
| JP2020528925A (ja) | 2020-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3706762A4 (fr) | N4-hydroxycytidine et dérivés et leurs utilisations anti-virales | |
| EP3788055A4 (fr) | Dérivés de neurostéroïdes et leurs utilisations | |
| EP3917529A4 (fr) | Composés et leurs utilisations | |
| EP3841096A4 (fr) | Dérivés de pyridinylméthylènepipéridine et leurs utilisations | |
| MA50256A (fr) | Composés de pyrazolopyrimidinone et leurs utilisations | |
| EP3694861A4 (fr) | Composés hétérocycliques et leurs utilisations | |
| EP3787607C0 (fr) | Compositions de caroténoïdes et leurs utilisations | |
| MA50618A (fr) | Polyrhérapies et leurs utilisations | |
| EP3849983A4 (fr) | Composés de triazolo-pyrimidine et leurs utilisations | |
| EP3917527A4 (fr) | Composés et leurs utilisations | |
| MA52365A (fr) | Composés et leurs utilisations | |
| MA52092A (fr) | Composés et leurs utilisations | |
| MA55385A (fr) | Composés et leurs utilisations | |
| EP3313530A4 (fr) | Dérivés de 4,6-pyrimidinylène et utilisations de ceux-ci | |
| EP3902530A4 (fr) | Nanovaccins polymères et leurs utilisations | |
| MA50413A (fr) | Dérivés de benzimidazole et leurs utilisations | |
| EP3790883A4 (fr) | Composés hétéroaryles et leurs utilisations | |
| EP3853216A4 (fr) | Composés substitués par pyridinyle et leurs utilisations | |
| EP4017843A4 (fr) | Dérivés de benzènesulfonamide et leurs utilisations | |
| EP3526215A4 (fr) | Dérivés de n-acyléthanolamide et leurs utilisations | |
| EP3323817A4 (fr) | Dérivés d'aniline pyrimidine et leurs utilisations | |
| MA52411A (fr) | Dérivés de 2,4-diaminoquinazoline et leurs utilisations médicales | |
| MA52976A (fr) | Dérivés de tétrahydrothiénopyridine n-substitués et leurs utilisations | |
| EP3535243A4 (fr) | Dérivés hétérocycliques tricycliques et leurs utilisations | |
| EP3630154A4 (fr) | Dérivés clivables de lipo-glycopeptides et leurs utilisations |